Welcome to SAMHSA's Publications site. In the future, you may be asked to respond to a CAPTCHA to access the site for added security.
This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.
This advisory defines attention deficit hyperactivity disorder in adults, and explains interactions with substance use disorders.
This advisory reviews diabetes and how it relates to mental illness, stress, and substance use disorders. It highlights ways to integrate diabetes care into behavioral health treatment, such as screening and intake, staff education, integrated care, and counseling support.
This advisory gives an overview of extended-release injectable naltrexone for people with opioid dependence. It discusses how it differs from other medication-assisted treatments, safety concerns, and patients most likely to benefit.
This advisory equips substance use treatment and service providers with information about eating disorders and their relationship to substance use disorders. It provides an overview of screening, referrals, and evidence-based treatments for eating disorders and lists resources for more information.
Millions of Americans have a substance use disorder. Find a treatment facility near you.
Free and confidential support for people in distress, 24/7.
Find treatment facilities confidentially and anonymously, 24/7.
Treatment referral and information, 24/7.